Vaccine Design Solution

Q: How accurate is in silico vaccine design prediction?

Our computational models are based on the latest bioinformatics databases and machine learning algorithms, placing prediction accuracy at the industry forefront. While in vitro and in vivo validation remain indispensable, In Silico design can reduce the number of candidates you need to focus on by over 90%, greatly optimizing the efficiency and focus of early development.

Q: What is the OMV Platform, and how does it enhance vaccine immunogenicity?

OMVs are nano-sized vesicles naturally released by Gram-negative bacteria during growth. They possess self-adjuvant activity (containing PAMPs) and are efficiently taken up by immune cells. As a multiple antigen display platform, OMV not only delivers multiple recombinant antigens but also naturally boosts immune stimulation, inducing stronger T-cell and B-cell responses.

Q: Does your target validation service include safety assessment?

Yes, it is mandatory. A crucial part of our target validation service is human homology analysis, a necessary step to exclude potential autoimmunity risks. We ensure that the screened antigen sequences fall within the safe similarity threshold to human endogenous protein sequences.

Q: Can I use these design services for cancer vaccines or autoimmune disease vaccines?

Absolutely. Our platforms are versatile. For instance, the epitope prediction algorithm can be used to identify tumor-specific neoantigens, and the target validation service can ensure the specificity of these neoantigens, which is highly valuable for the design of personalized cancer vaccines.

Q: How long does it typically take from starting in silico design to obtaining a prototype vaccine candidate?

This timeframe depends on the complexity of the target and the chosen display platform. Typically, the process from In Silico design to determining the validated antigen sequence takes approximately 4-6 weeks. Including OMV construction and initial production, the entire process can be completed within 3-4 months, which is significantly faster than traditional methods.

Creative Biolabs offers advanced vaccine design solutions, integrating computational biology, target validation, and cutting-edge antigen display technologies to comprehensively accelerate our clients' vaccine research and development process. Our services begin with highly efficient in silico epitope prediction, proceed through rigorous target specificity validation (such as NGS), and culminate in the realization of highly immunogenic multiple antigen display via platforms like OMV. We are committed to providing clients with fast, cost-effective, and optimized vaccine candidates to address the challenges posed by complex pathogens and multivalent vaccine design.

Vaccine Design Core Challenges and Solutions

Creative Biolabs provides comprehensive vaccine design solutions focused on overcoming industry challenges, such as the accuracy of immunogenicity prediction, safety risks, and the difficulty of constructing multivalent vaccines. Our core service strategies and strengths include:

Accelerating Early R&D and Optimizing Costs

Applying advanced computational methods (in silico) for screening, drastically reducing the cycle from months to weeks, and significantly lowering early-stage R&D costs.

In-Depth Target Validation and Safety Assurance

Utilizing technologies like NGS and functional biomarkers for in-depth validation of candidate targets, ensuring high specificity and ruling out potential risks of autoimmunity.

Multiple Antigen Display and Broad Immunity

Employing multiple antigen display technology (such as the OMV Platform) to effectively induce a broad immune response against multiple antigens or epitopes, especially suitable for combating complex or multi-strain pathogens.

Solving Core Technical Bottlenecks

Committed to helping clients resolve all core technical challenges from target discovery to antigen presentation, ensuring candidate vaccines have the highest potential for success.

Our Core Vaccine Design Services

In Silico Vaccine Design Services

Utilizing powerful bioinformatics tools and databases for high-throughput, rational antigen screening and optimization, enabling rapid vaccine prototype design.

Epitope Predicting Algorithm: Predicts T-cell (MHC Class I/II) and B-cell epitopes. Uses AI models to score the immunogenicity of potential antigens, guiding subsequent experimental design.
epiVacKit - Epitope-driven Vaccine Design: A customized solution dedicated to epitope vaccine design, combining prediction results with synthesis optimization to achieve precise peptide or DNA/RNA vaccine design.

Vaccine Target Validation Services

Through experimental means, perform deep functional and safety validation on targets obtained from computational or in vitro screening.

Biomarker Discovery & Development: Discover and validate biomarkers related to protective immune response to the vaccine, used to evaluate the effectiveness of target validation or as preclinical efficacy indicators.
NGS Sequencing: Utilizes high-throughput sequencing technology (such as whole-genome or transcriptome sequencing) to analyze pathogen variation, identify immune evasion mechanisms, or assess host immune response, thereby ensuring the scientific validity of target selection.

Multiple Antigen Display Technology for Vaccine Design

Addresses the core challenge of multivalent vaccines by efficiently displaying multiple antigens via carriers to enhance immunogenicity and breadth of immune response.

Outer Membrane Vesicle Platform: Utilizes OMVs secreted by bacteria as natural immune stimulants and antigen delivery systems. OMVs possess natural adjuvant effects and can efficiently display multiple recombinant antigens, inducing strong humoral and cellular immune responses.

Core Technology Platforms and Innovation

In Silico Computational Models

Core Advantage: High-precision T/B cell epitope prediction, avoiding autoimmunity risks.
Application Area: Rational design of peptide, DNA/RNA vaccines.

Next-Generation Sequencing (NGS)

Core Advantage: Deep analysis of pathogen genomes and host immunome.
Application Area: Target identification, pathogen variation monitoring, immune response assessment.

Outer Membrane Vesicle (OMV) Platform

Core Advantage: Natural self-adjuvant effect, capable of displaying multivalent antigens simultaneously, inducing mucosal immunity.
Application Area: Bacterial vaccines, multivalent Virus-Like Particle (VLP) vaccines.

epiVacKit

Core Advantage: Integrated epitope-driven design tool, accelerating the output of prototype candidates.
Application Area: Rapid response design for emerging infectious disease vaccines.

Service Standard Workflow

Target Identification and Data Analysis

Step: Collect pathogen genome/proteome data. Utilize bioinformatics tools for sequence analysis and T/B cell epitope prediction.
Output: A ranked list of potential antigen and epitope candidates.

Safety and Specificity Assessment

Step: Human homology comparison analysis (to exclude autoimmunity risks). Physicochemical property and structural modeling.
Output: Rationally screened and optimized antigen sequences.

Target Functional Validation

Step: Screen and validate the in vitro immunogenicity of antigens through NGS or other high-throughput functional assays (e.g., ELISA/ELISpot).
Output: Final antigen candidates with high immunogenicity and low risk.

Antigen Construction and Display

Step: Select the appropriate display platform (e.g., OMV, VLP, recombinant protein) based on the vaccine type (peptide, subunit, multivalent). Perform antigen expression, purification, and modification.
Output: Lab-scale prototype vaccine candidates.

Preclinical Evaluation and Optimization

Step: Provide preliminary immunogenicity testing and adjuvant screening recommendations in animal models.
Output: A comprehensive evaluation report and next-step development suggestions.

Partner with Creative Biolabs Now!

Creative Biolabs Advantages

Multidisciplinary Expert Team

Our team combines expertise in computational biology, immunology, molecular biology, and bioengineering, ensuring comprehensive design.

Comprehensive Platform Integration

Seamlessly integrates advanced in silico tools with the high-efficiency OMV multiple antigen display technology, offering a one-stop, end-to-end solution.

High Efficiency and Low Cost

Significantly reduces expensive wet-lab workload through rational design and computational prediction, accelerating the candidate screening cycle.

Focus on Multivalent and Complex Pathogens

Especially skilled at using OMV and viral vector technologies to solve complex multivalent vaccine design challenges that traditional methods struggle to overcome.

A presentation slide highlighting the advantages of Creative Biolabs related to vaccine design solutions.

Customer Reviews

"Creative Biolabs' in silico design service is impressive. Their epitope prediction accuracy is very high, helping us quickly focus our peptide vaccine efforts on the most promising candidates, saving months of time and significant synthesis costs."

— Dr. Smith, R&D Director

"We utilized their OMV Platform to display a complex bacterial antigen. The natural adjuvant effect of OMV is truly powerful, inducing humoral and cellular immune responses far exceeding our expectations in mouse models. Their technical support is highly professional."

- Prof. Rodriguez, Infectious Disease

"During the target validation phase, the NGS sequencing and biomarker discovery services provided by Creative Biolabs were extremely rigorous, successfully ruling out a potential safety hazard target and securing the long-term safety and success rate of our project."

- Dr. Kim, Early Phase Development Manager

Case Study

Toxoplasma gondii TG_200 mRNA-LNP Toxoplasmosis Vaccine

Background

A study aimed to develop a safe and effective vaccine against Toxoplasma gondii (a zoonotic parasite causing severe toxoplasmosis), given the lack of ideal drugs/vaccines. It focused on TGGT1_216200 (TG_200), a T. gondii molecule screened via bioinformatics for strong T/B-cell epitopes, encapsulated in lipid nanoparticles (LNPs) to form TG_200 mRNA-LNP.

Solution

BALB/c mice were grouped (TG_200 mRNA-LNP, LNP control, blank control) and immunized intramuscularly thrice. Key steps included: bioinformatic epitope prediction (DNASTAR, IEDB), mRNA construct design (5'cap/UTR, TG_200 ORF, 3'UTR, Poly-A tail), LNP encapsulation (95.67% efficiency), and assessments of humoral/cellular immunity (ELISA, flow cytometry, CTL assay) post-immunization, plus T. gondii RH strain challenge.

Result

The vaccine induced robust immunity: elevated anti-T. gondii IgG (higher IgG2a/IgG1, Th1-dominant), increased cytokines (IL-12, IFN-γ, IL-4, IL-10), activated DCs (higher CD83/CD86/MHC), and enhanced CTL activity. Post-challenge, TG_200 mRNA-LNP mice survived ~19.3 days (vs control <8 days, P<0.001); adoptive transfer of serum/splenocytes also prolonged survival, proving it a promising candidate.

A presentation slide displaying an experimental design and immune schematic diagram of an mRNA-LNP vaccine.

An mRNA-LNP Vaccine Experimental Design and Immune Schematic Diagram.
Zhang, Yizhuo, et al. "Immunization with a novel mRNA vaccine, TGGT1_216200 mRNA-LNP, prolongs survival time in BALB/c mice against acute toxoplasmosis." Frontiers in immunology 14 (2023): 1161507. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2023.1161507

FAQs of Vaccine Design Solution

How accurate is in silico vaccine design prediction?

Our computational models are based on the latest bioinformatics databases and machine learning algorithms, placing prediction accuracy at the industry forefront. While in vitro and in vivo validation remain indispensable, In Silico design can reduce the number of candidates you need to focus on by over 90%, greatly optimizing the efficiency and focus of early development.

What is the OMV Platform, and how does it enhance vaccine immunogenicity?

OMVs are nano-sized vesicles naturally released by Gram-negative bacteria during growth. They possess self-adjuvant activity (containing PAMPs) and are efficiently taken up by immune cells. As a multiple antigen display platform, OMV not only delivers multiple recombinant antigens but also naturally boosts immune stimulation, inducing stronger T-cell and B-cell responses.

Does your target validation service include safety assessment?